

Oregon Medical Board  
**BOARD ACTION REPORT**  
**August 15, 2018**

The information contained in this report summarizes new, interim, and final actions taken by the Oregon Medical Board between July 16, 2018, and August 15, 2018.

Scanned copies of Interim Stipulated Orders, Orders of Emergency Suspension, Stipulated Orders, Final Orders, Termination Orders, Modification Orders and Voluntary Limitations are included at the end of this report in the order that they appear in the report. These orders are marked with an \* asterisk. **Scanned copies of Consent Agreements are not posted, as they are not disciplinary action and impose no practice limitations.** Complaint and Notices of Proposed Disciplinary Action are not listed in this report, as they are not final actions by the Board. Both Orders, however, are public and are available upon request.

Printed copies of the Board Orders not provided with this report are available to the public. To obtain a printed copy of a Board Order not provided in this report, please complete the License Verification and Malpractice Report Request (<http://www.oregon.gov/OMB/ombforms1/request-licensee-info-verification.pdf>) found under the Forms link on the Board's web site. Submit it with the \$10.00 fee *per licensee* and mail to:

**Oregon Medical Board**  
**1500 SW 1st Ave, Ste 620**  
**Portland, OR 97201**

*Copies of the Orders listed below are mailed to Oregon hospitals where the Licensee had self-reported that he/she has privileges.*

---

**\*Delabruere, Beverly Ann, MD; MD15031; Oregon City, OR**

On July 30, 2018, Licensee entered into an Interim Stipulated Order to voluntarily cease initiating or begin tapering opioids for chronic pain patients; cease initiating or begin tapering concurrent benzodiazepines; cease initiating treatment for opioid use disorder with scheduled medications; limit prescribing for acute pain; cease initiating or begin tapering concurrent benzodiazepines; cease prescribing concurrent muscle relaxants with opioids; and comply with federal regulations when prescribing buprenorphine or buprenorphine/naloxone for opioid use disorder or chronic pain.

**Harless, Megan Louise, PA; PA01404; Hillsboro, OR**

On July 20, 2018, Licensee entered into a Consent Agreement for Re-Entry to Practice with the Board. In this Agreement, Licensee agreed to specific requirements regarding supervision and chart review from her supervising physician; that that her supervising physician would submit reports to the Board; to practice in a clinic setting two months; to follow the practice recommendations of a pre-approved healthcare provider; and to complete 23.5 hours of AMA Category I CME.

**Jimenez, Anna Maria, MD; MD21969; Hillsboro, OR**

On August 6, 2018, the Board issued an Order Terminating Consent Agreement for Re-Entry to Practice. This Order terminates Licensee's March 15, 2018, Consent Agreement for Re-Entry to Practice.

**Jonsson, Martina Charlotte, MD; MD187142; Eugene, OR**

On July 23, 2018, Applicant entered into a Consent Agreement for Re-Entry to Practice with the Board. In this Agreement, Applicant agreed to practice under the supervision of a pre-approved mentor, to include chart review and reports to the Board by the mentor; and to obtain board certification in psychiatry.

**Reddy, Latha N, PA; PA184460; Portland, OR**

On July 18, 2018, Applicant entered into a Consent Agreement for Re-Entry to Practice with the Board. In this Agreement, Applicant agreed to specific requirements regarding chart review from her supervising physician; to practice at least 16 hours per week; and to the submission of quarterly reports to the Board from the supervising physician regarding Applicant's progress in the return to the practice of medicine.

**Rubin, Zarya Alexandra, MD; MD181189; Portland, OR**

On August 8, 2018, the Board issued an Order Terminating Consent Agreement for Re-Entry to Practice. This Order terminates Licensee's May 8, 2017, Consent Agreement for Re-Entry to Practice.

**Sandstrom, Patricia Marie, MD; MD165742; Portland, OR**

On August 15, 2018, Licensee entered into a Consent Agreement for Re-Entry to Practice with the Board. In this Agreement, Licensee agreed to practice under the supervision of a pre-approved mentor for six months, to include chart review and reports to the Board by the mentor; and to submit 83.75 hours of AMA Category I CME.

**Swanson, Geoffrey Norman, MD; Applicant; Medford, OR**

On August 15, 2018, Applicant entered into a Consent Agreement for Re-Entry to Practice with the Board. In this Agreement, Applicant agreed to practice under the supervision of a pre-approved mentor for three months, to include chart review and reports to the Board by the mentor.

---

If you have any questions regarding this service, please call the Board at (971) 673-2700 or toll-free within Oregon at (877) 254-6263.



1           3.3     Licensee must immediately begin to taper opioid medications for any chronic pain  
2 patient with a morphine equivalent dose (MED) over 90 by at least 10% per month until patient's  
3 MED is 90 or less. Alternatively, Licensee may transfer the care of any patient with an MED  
4 over 90 to another physician. Licensee may continue to prescribe greater than 90 MED for  
5 chronic pain for patients who are currently enrolled in hospice or who are currently receiving end  
6 of life care. Licensee must certify on the written prescription that the patient is a hospice patient  
7 or receiving end of life care.

8           3.4     Licensee may treat patients for acute pain for no more than 30 days per year, with  
9 a maximum MED of 50.

10          3.5     For patients taking benzodiazepines and opioids (to include buprenorphine or  
11 buprenorphine/naloxone), Licensee must begin to taper benzodiazepines after opioids have been  
12 tapered to 90 MED or less. Benzodiazepines must be tapered by at least 10% per month until the  
13 patient is weaned off benzodiazepines. Alternatively, Licensee may transfer the care of any  
14 patient for whom she is prescribing benzodiazepines and opioids to another physician. Licensee  
15 may continue to prescribe benzodiazepines to patients who are currently enrolled in hospice or  
16 who are currently receiving end of life care. Licensee must certify on the written prescription  
17 that the patient is a hospice patient or receiving end of life care.

18          3.6     Licensee must not concomitantly prescribe opioids with benzodiazepines  
19 following tapering as outline in terms 3.2 and 3.4.

20          3.7     Licensee must not concomitantly prescribe opioids with carisoprodol (Soma).

21          3.8     Licensee may continue to prescribe buprenorphine or buprenorphine/naloxone for  
22 the treatment of opioid use disorder or for existing patients taking the medications for chronic  
23 pain. Licensee must comply with all federal regulations applicable to the use of buprenorphine  
24 and buprenorphine/naloxone.

24          3.9     Licensee understands that violating any term of this Order will be grounds for  
25 disciplinary action under ORS 677.190(17).

26          3.10    Licensee understands this Order becomes effective the date she signs it.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26

4.

At the conclusion of the Board's investigation, the Board will decide whether to close the case or to proceed to some form of disciplinary action. If the Board determines, following that review, not to lift the requirements of this Order, Licensee may request a hearing to contest that decision.

5.

This order is issued by the Board pursuant to ORS 677.410, which grants the Board the authority to attach conditions to the license of Licensee to practice medicine. These conditions will remain in effect while the Board conducts a complete investigation in order to fully inform itself with respect to the conduct of Licensee. Pursuant to ORS 677.425, Board investigative materials are confidential and shall not be subject to public disclosure, nor shall they be admissible as evidence in any judicial proceeding. However, as a stipulation this Order is a public document and is reportable to the National Databank and the Federation of State Medical Boards.

IT IS SO STIPULATED THIS 30 day of July, 2018.

  
~~BEVERLY ANN DELABRUERE, MD~~  
BEVERLY ANN DELABRUERE, MD

IT IS SO ORDERED THIS 31 day of July, 2018.

OREGON MEDICAL BOARD  
State of Oregon

  
NICOLE KRISHNASWAMI, JD  
INTERIM EXECUTIVE DIRECTOR